Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.

Mennuni C, Ugel S, Mori F, Cipriani B, Iezzi M, Pannellini T, Lazzaro D, Ciliberto G, La Monica N, Zanovello P, Bronte V, Scarselli E.

Cancer Res. 2008 Dec 1;68(23):9865-74. doi: 10.1158/0008-5472.CAN-08-1603.

2.

Altered macrophage differentiation and immune dysfunction in tumor development.

Sica A, Bronte V.

J Clin Invest. 2007 May;117(5):1155-66. Review.

3.

Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.

Savage P, Millrain M, Dimakou S, Stebbing J, Dyson J.

Tumour Biol. 2007;28(2):70-6. Epub 2007 Jan 29.

PMID:
17264539
4.

Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.

Johnson LA, Heemskerk B, Powell DJ Jr, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA.

J Immunol. 2006 Nov 1;177(9):6548-59.

5.

Artificial antigen-presenting cells: artificial solutions for real diseases.

Oelke M, Krueger C, Giuntoli RL 2nd, Schneck JP.

Trends Mol Med. 2005 Sep;11(9):412-20. Review.

PMID:
16103011
6.

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, Hörig H, Marincola FM.

J Clin Invest. 2005 Jul;115(7):1903-12. Epub 2005 Jun 2.

7.

A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo.

Carey B, DeLay M, Strasser JE, Chalk C, Dudley-McClain K, Milligan GN, Brunner HI, Thornton S, Hirsch R.

Clin Immunol. 2005 Jul;116(1):65-76.

PMID:
15925833
8.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA.

J Clin Oncol. 2005 Apr 1;23(10):2346-57.

9.

The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice.

Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA.

J Immunol. 2005 Mar 1;174(5):2563-72.

10.

Mechanisms and functional significance of tumour-induced dendritic-cell defects.

Gabrilovich D.

Nat Rev Immunol. 2004 Dec;4(12):941-52. Review.

PMID:
15573129
11.

Part I: Vaccines for solid tumours.

Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D.

Lancet Oncol. 2004 Nov;5(11):681-9. Review. Erratum in: Lancet Oncol. 2005 Jan;6(1):4.

PMID:
15522656
12.

Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes.

De Palma R, Marigo I, Del Galdo F, De Santo C, Serafini P, Cingarlini S, Tüting T, Lenz J, Basso G, Milan G, Zanovello P, Bronte V.

Cancer Res. 2004 Nov 1;64(21):8068-76.

13.

Cancer immunotherapy: moving beyond current vaccines.

Rosenberg SA, Yang JC, Restifo NP.

Nat Med. 2004 Sep;10(9):909-15.

14.

HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement.

Oelke M, Schneck JP.

Clin Immunol. 2004 Mar;110(3):243-51. Review.

PMID:
15047202
15.

Priming of naive T cells inside tumors leads to eradication of established tumors.

Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX.

Nat Immunol. 2004 Feb;5(2):141-9. Epub 2004 Jan 4.

16.

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells.

Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP.

Nat Med. 2003 May;9(5):619-24. Epub 2003 Apr 21.

PMID:
12704385
17.

Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients.

Meidenbauer N, Marienhagen J, Laumer M, Vogl S, Heymann J, Andreesen R, Mackensen A.

J Immunol. 2003 Feb 15;170(4):2161-9.

18.

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O, Guillaume P, Batard P, Luescher IF, Lejeune F, Liénard D, Rufer N, Dietrich PY, Speiser DE, Cerottini JC.

Immunol Rev. 2002 Oct;188:81-96. Review.

PMID:
12445283
19.

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.

Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA.

Science. 2002 Oct 25;298(5594):850-4. Epub 2002 Sep 19.

20.

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH.

J Immunol. 2002 May 1;168(9):4272-6.

Supplemental Content

Support Center